The European Commission has proposed a close to 50% real-terms increase in its next research funding cycle, lifting the 2028–34 programme to €175 billion — the clearest signal yet that Brussels intends to convert Washington's scientific turmoil into a durable competitive advantage.

The proposal, highlighted in a Nature editorial marking ten years since the UK's Brexit vote, sits alongside a nearly €900-million Choose Europe initiative launched last year. That money is largely directed at making European Research Council grants more attractive and pulling top talent toward institutions in under-performing EU regions — a deliberate counter to the US funding instability that has already pushed dozens of researchers toward France.

The demand-side opportunity

The timing is not accidental. Australia, India and Japan are all seeking deeper research collaboration with the EU through Horizon Europe, and the United Kingdom is working to realign its science relationship with the bloc after formally leaving in January 2020. Brexit's costs remain measurable: UK GDP sits an estimated 4–5% below where it would have been inside the EU, and consistent polling shows many Leave voters regret their choice.

For R&D managers outside Europe, the practical question is access. Horizon Europe represents only about 10% of the EU's public R&D spending, but it functions as the world's largest fund for international research cooperation. Association deals — the mechanism the UK is negotiating and that Canberra, Tokyo and Delhi are eyeing — determine whether national institutions can lead consortia and draw down grants.

Europe's bargaining position is stronger than its self-image suggests. The EU or Europe as a whole ranks first or second globally on publication volume, research impact and PhD graduates. While the US and China decouple from each other scientifically, the EU maintains or expands collaborations with both, and all three blocs are rapidly growing ties with low- and middle-income countries.

Where the money actually goes

The Africa portfolio illustrates the scale of the strategy. By 2027 the Commission will have spent almost €1.8 billion (US$2.1 billion) on joint research projects through Horizon Europe's Africa Initiative, which began in 2021, alongside €150 billion for green and digital transitions under the Global Gateway Africa–Europe Investment Package.

The aggregate spending picture is more mixed. The US and China devote a higher share of GDP to R&D than European nations. On public spending, however, EU countries match the US at roughly 0.65% of GDP and sit ahead of China — meaning the private-sector gap, not public commitment, is Europe's structural weakness.

The innovation paradox, quantified

That weakness has a name in Brussels policy circles: the innovation paradox. Cutting-edge European research rarely commercializes at the scale seen in the US or China. One measurable indicator: only two European firms — Volkswagen and Roche — appear among the top ten global companies for R&D investment.

The Commission has diagnosed causes in a series of expert competitiveness reports. Two stand out. First, a cultural fear of failure that differs from the risk appetite in US and Chinese innovation systems. Second, a structural burden on start-ups: companies operating across the EU must navigate regulatory, tax, employment and legal frameworks that differ by member state — fragmentation that US and Chinese competitors do not face.

Three countermeasures are in motion. The Commission will propose a European Research Area (ERA) Act this year, which requires member-state support if legislation is to be finalized before the current seven-year financial cycle ends in 2027. On innovation, work is under way on Europe-wide rules for start-ups, and a €5-billion public–private Scaleup Europe Fund aims to keep future large tech companies on the continent. Red-tape reduction is a stated priority, though the editorial cautions that regulation also shapes innovation and protects people and the environment — the goal is streamlining, not dismantling.

The headwinds

Budget pressure is the immediate threat. Sustained US pressure on Europe to raise defence spending is draining public budgets and encroaching on research funding. Parallel moves to militarize European research are under way, and Nature has previously argued these should not hand governments carte blanche to interfere in the inner workings of science.

The editorial's proposed alternative is science as diplomacy: the rules of the next funding programme should make explicit that the EU wants collaborations drawing on specialisms worldwide, with benefits distributed to all participants. That framing positions Europe as the anchor of a global science ecosystem built on open science and academic freedom — and, in the editorial's view, as a model for innovation that delivers social, economic and environmental returns rather than returns to founders and investors alone.

For research administrators, the actionable timeline is short. The ERA Act needs member-state agreement before 2027, the €175-billion framework takes effect in 2028, and the current window of US-driven talent mobility — the recruitment momentum behind Choose Europe — may not stay open indefinitely. Whether the near-doubling of ambition survives defence-spending pressure in member-state budget negotiations will determine if Europe consolidates its position or repeats the fragmentation costs that Brexit imposed on UK science.